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Abstract
Background: Experimental and natural human adenovirus-36 (Adv36) infection of multiple animal species results in obesity
through increasing adipogenesis and lipid accumulation in adipocytes. Presence of Adv36 antibodies detected by serum
neutralization assay has previously been associated with obesity in children and adults living in the USA, South Korea and
Italy, whereas no association with adult obesity was detected in Belgium/the Netherlands nor among USA military
personnel. Adv36 infection has also been shown to reduce blood lipid levels, increase glucose uptake by adipose tissue and
skeletal muscle biopsies, and to associate with improved glycemic control in non-diabetic individuals.
Principal Findings: Using a novel ELISA, 1946 clinically well-characterized individuals including 424 children and 1522 non-
diabetic adults, and 89 anonymous blood donors, residing in central Sweden representing the population in Stockholm
area, were studied for the presence of antibodies against Adv36 in serum. The prevalence of Adv36 positivity in lean
individuals increased from ,7% in 1992–1998 to 15–20% in 2002–2009, which paralleled the increase in obesity prevalence.
We found that Adv36-positive serology was associated with pediatric obesity and with severe obesity in females compared
to lean and overweight/mildly obese individuals, with a 1.5 to 2-fold Adv36 positivity increase in cases. Moreover, Adv36
positivity was less common among females and males on antilipid pharmacological treatment or with high blood
triglyceride level. Insulin sensitivity, measured as lower HOMA-IR, showed a higher point estimate in Adv36-positive obese
females and males, although it was not statistically significant (p = 0.08).
Conclusion: Using a novel ELISA we show that Adv36 infection is associated with pediatric obesity, severe obesity in adult
females and lower risk of high blood lipid levels in non-diabetic Swedish individuals.
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Introduction
Human adenovirus-36 (Adv36) was first isolated in 1980 [1] and
belongs to the group of 54 known human adenovirus serotypes
generally associated with infections in the respiratory or gastro-
intestinal tract or the conjunctiva. The 54 types are grouped into
seven species based on their immunochemical responses, nucleic
acid characteristics, hexon and fiber protein characteristics,
biological properties, and phylogenetic analysis, with Adv36
belonging to the adenovirus-D subgroup (Adv-D) [2,3]. It has
been demonstrated that experimental and natural Adv36 infection
of multiple animal species resulted in obesity through increasing
proliferation and differentiation of preadipocytes and lipid
accumulation in mature adipocytes [4–12]. Most subsequent
papers on Adv36 and obesity in man have shown that humans
with evidence of prior, natural Adv36 infection are heavier than
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uninfected individuals [13–19]. The data on association between
Adv36 and obesity in adults differ between studies being somewhat
inconsistent, but the findings in children consistently associate
Adv36 infection with obesity.
In contrast to most cases of obesity, Adv36-associated obesity
has been associated with lower levels of blood lipids in animal [5]
and adult man [13,14]. Also, Adv36 is reported to improve
glycemic control in rat [6] and in chow-fed and in high-fat diet-fed
mice by enhancing glucose uptake in adipose tissue, skeletal
muscle and reduce hepatic glucose release [20–22]. Further,
Adv36 was associated with enhanced insulin sensitivity in 1507
lean, overweight and obese otherwise healthy adults and children
of different ethnicities living in the USA [22].
All of the studies published previously used the serum
neutralization assay (SNA) to detect antibodies against Adv36.
The SNA is quite time consuming and expensive, taking
approximately 2 weeks to perform. Hence, it is not well suited
for rapid screening for Adv36 infection.
In this paper we have described a new method for determining
evidence of Adv36 infection. Using the ELISA we tested the
hypotheses that Adv36 was present within the Swedish population
living in the area of the capital Stockholm, that Adv36 was
associated with obesity in children and adults in Stockholm area,
that Adv36 was associated with lower blood lipid levels, and that
Adv36 was associated with insulin sensitivity in non-diabetic
individuals.
Materials and Methods
Ethics Statement
A total of 424 children and 1522 adults from Sweden, and 456
anonymous human serum samples from Sweden, the USA,
Finland and South Korea, were studied in this project. The study
groups and the studies they were used in are listed in Table 1. This
project is in compliance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki). The ethical
committee of Karolinska Institutet approved the study and
informed consent was obtained from all participants, but for the
Swedish commercial anonymous blood donor samples. The
informed consent was written, but for in the Stockholm Diabetes
Prevention Program (SDPP). For participants in SDPP, verbal
informed consent was obtained according to a procedure
approved by the ethics committee. This was documented in the
SDPP research protocol, a procedure fulfilling the Swedish legal
requirements. Also the guardians of participating children (age
below 16 years) gave written consent.
The vaccination of rabbits was performed in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Wisconsin.
Obese Children
Children aged 10–18 years and referred to the national
pediatric obesity clinic center at Karolinska University Hospital
in Huddinge, Stockholm County, were studied. The children
studied can be regarded as representing pediatric obesity patients
in the Stockholm County population because children in Stock-
holm County seeking health care for obesity would be referred to
this clinic. Serum and clinical data from the 221 obese patients,
including 113 girls and 108 boys, were collected between 2003 and
2007 (Table 1). Date of serum collection and date of clinical data
collection for each patient occurred within 6 months. The vast
majority (71%) of the children were sampled before any treatment
of obesity, whereas for the rest (29%) information on treatment
prior to sampling was unavailable. Most of the children were obese
(101 females and 98 males) and a few were overweight (12 females
and 10 males) according to international cutoff limits [23]. The
distribution of BMI SDS for these children had a median (25th,
75th percentiles) of 5.5 (4.4, 6.4) and ranged between 2.2 and 10.5
[24] (Fig. 1). (BMI SDS, or BMI Z-Score, is the number of
standard deviations the child’s BMI is from French population
BMI mean adjusted for the child’s age and gender according to
Rolland-Cachera et al, 1982 [24]). Clinical data available for all
patients included levels for fasting plasma triglycerides, total
cholesterol, LDL, HDL, glucose and insulin. These levels were
measured by the Karolinska University Hospital’s accredited
chemistry laboratory. Insulin sensitivity (Si) and acute insulin
response (AIR), obtained by means of frequent sampling insulin
modified glucose tolerance test [25], were available for the 71% of
individuals known not to have had prior treatment of obesity
(Table 2).
Lean Children
Two hundred-three lean controls aged 16–17 years were
collected from high schools in Stockholm between 2004 and
2006 (Table 1). The distribution of BMI SDS for these lean
children had a median (25th, 75th percentiles) of 0.2 (20.2, 0.8)
and ranged from 21.4 to 1.8 [24] (Fig. 1). Serum and data on age,
gender, body weight, height, and school name were available.
Schools with a proportion higher than average of children with
non-Swedish origin were excluded. Serum collection and clinical
data collection for each child occurred on the same day.
Adult Severely Obese Female Patients from Obesity
Surgery Clinics in Stockholm
Females referred to the obesity surgery clinics at Danderyd
Hospital and Ersta Hospital in Stockholm for obesity treatment
between 2008 and 2010 were studied. Those with BMI$35 kg/
m2, no known molecular cause of obesity but with data on fasting
plasma triglycerides, total cholesterol, glucose and serum insulin
were included. Females with T2DM were excluded. To exclude
those with prediabetes, HOMA-IR,6.6 was used as an arbitrary
criterion for inclusion. In total, 241 females aged between 19 and
67 years (age; mean 6 SEM: 40.460.63 years) were included in
the study (Table 1). Serum and data on fasting plasma
triglycerides, total cholesterol, glucose, fasting serum insulin, and
HOMA-IR ( = glucose*insulin/22.5, reflects insulin resistance)
were used (Table 2). Analyses of glucose, insulin, cholesterol and
triglycerides were performed by the Karolinska University
Hospital’s accredited chemistry laboratory. In short, glucose
(reference (normal) interval 4.0–6.0 mmol/L) was analyzed on a
Beckman Coulter LX (Beckman Coulter AB, Bromma, Sweden),
insulin (reference interval 2.6–25.9 mU/ml) on a Modular E170
(Roche Diagnostics AB, Bromma, Sweden), cholesterol (reference
interval plasma and serum for age 31–50 years: 3.3–6.9 mmol/l;
.50 years: 3.9–7.8) and triglycerides (reference interval plasma
and serum for age .18 years: 0.45–2.6 mmol/l) on a Beckman
Coulter DXC800 (Beckman Coulter AB).
Adult Obese, Overweight and Lean Female and Male
Individuals from the General Stockholm Population
The Stockholm Diabetes Prevention Program
(SDPP). Individuals selected from the longitudinal popula-
tion-based SDPP cohort of females and males living in Stock-
holm County, aged 35–56 years at baseline, were studied. The
baseline sampling was performed in 1992–1998 and follow-up
Adv36 and Obesity
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was performed in 2002–2006 (Table 1). A small set of serum
samples collected at baseline was analyzed for prevalence of
Adv36 antibodies 1992–1998: 125 females (age; mean 6 SEM:
46.265.4 years) and 55 males (age; mean 6 SEM:
47.064.9 years) that were lean (BMI 20–24.9 kg/m2) at baseline
with fasting serum glucose ,6.1 mM and normal oral glucose
tolerance defined as glucose level ,7.8 mM 2 h after 75 g oral
glucose tolerance test (OGTT) [26]. For Adv36 prevalence
Table 1. Study groups and the studies they were used for.
Study group City Age (years) Year collected Lean (n) Overweight/obese (n) Study
Pediatric obesity patients Stockholm 10–18 2003–2007 113 f, 108 m 3a
High school students Stockholm 16–17 2004–2006 106 f, 97 m 2, 3a
Obesity surgery clinic Stockholm 19–67 2008–2010 241 f 3b
SDPP Stockholm 35–55 1992–1998 125f, 55m 2
SDPP Stockholm 45–65 2002–2006 255 f, 219 m 252 f, 218 m 2,3b
SMC Uppsala 55–80 2004 81 f 76 f 2,3b
Anonymous blood donors Stockholm 19–69 2009 55 f, 34 m 2
Anonymous samples USA, Finland, South
Korea
367 1
f: females, m: males.
Study 1: Comparison between ELISA and serum neutralization assay.
Study 2: Adv36 prevalence in Sweden.
Study 3: Association analyses between Adv36 and metabolic parameters in a) children and b) adults.
doi:10.1371/journal.pone.0041652.t001
Figure 1. Distribution of BMI in analyzed children and adults. A) Distribution of BMI SDS (BMI Z-Score) adjusted for age and gender according
to Rolland-Cachera et al, 1982 [24] among lean (BMI SDS: 21.421.8) and overweight/obese (BMI SDS: 2.2–10.5) children; B) Distribution of BMI in the
lean (BMI,25 kg/m2), overweight and mildly obese (28,BMI,35 kg/m2), and severely obese (BMI$35 kg/m2) adults studied; C) BMI-SDS distribution
of those children positive for Adv36 in ELISA; D) BMI-distribution of those adults positive for Adv36 in ELISA.
doi:10.1371/journal.pone.0041652.g001
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analysis 2002–2006 and analysis of Adv36 association to obesity,
serum and data used in this study were from the follow-up
collected in 2002–2006. Individuals with BMI$28.0 kg/m2 were
selected to the overweight/mild obesity group consisting of 218
males (age; mean 6 SEM: 56.260.33, range 46–66 years) and
252 females (age; mean 6 SEM: 55.560.32, range 44–63 years).
A lean group (BMI 20.0–24.9 kg/m2) was matched by age and
sex to the overweight/mild obesity group and included 219 males
(age; mean 6 SEM: 56.860.34, range 46–65 years) and 255
females (age; mean 6 SEM: 55.660.32, range 44–63 years). All
selected individuals had normal oral glucose tolerance and
normal fasting serum glucose levels at both baseline and follow-
up. Serum and clinical data on BMI, fasting serum triglycerides,
total cholesterol, glucose, insulin and HOMA-IR were used
(Table 2). Serum and clinical data were collected at the same
date for each individual. Concentration of serum glucose was
analyzed in duplicate by a glucose oxidase method using a
Yellow Springs Glucose Analyzer (Yellow Springs, OH, USA).
Serum insulin was assayed by radioimmunoassay, using in-house
antibodies, human insulin as a standard, and charcoal addition to
separate antibody-bound and free serum insulin [27]. Cholesterol
and triglyceride levels were measured by the Karolinska
University Hospital’s accredited chemistry laboratory as de-
scribed for the obesity surgery clinical patients.
The Swedish Mammography Cohort (SMC). Adult fe-
males selected from the population-based The Swedish Mam-
mography Cohort (SMC) females in Uppsala County were studied
for Adv36 antibodies. From 1987 to 1990, 74% of all females
living in Uppsala County and born between 1914–1948 returned a
completed questionnaire on diet, weight, height and education.
During 2003–2009 a subgroup of those (5022 females) participated
in a physical examination after an overnight fast where BMI,
plasma and serum were obtained. For this study, from the 5022
females 76 overweight/obese (BMI$28.0 kg/m2) and 81 lean
(BMI = 20.0–24.9 kg/m2) non-diabetic females examined in 2004
were randomly selected (Table 1). Serum and clinical data were
collected at the same date for each individual. No metabolic blood
chemistry data was used.
Combining females from SDPP and from SMC there were in
total 328 overweight/obese females (age; mean 6 SEM:
57.860.37 years) and 336 lean females (age; mean 6 SEM:
57.860.36 years) with age range 44–80 years.
Anonymous blood donors. Serum was collected in 2009
from 89 healthy anonymous blood donors at Karolinska Univer-
sity Hospital in Huddinge. They were 34 males and 55 females
aged 19–69 years, median age 40 years (Table 1).
Serum Neutralization Assay (SNA) for Viral Antibodies
Positive control serum samples were produced by inoculating
three rabbits with killed Adv36 emulsified in Freund’s adjuvant via
intramuscular injection and collection of blood 29 days post-
injection (Obetech, Richmond,VA). Human serum samples
(n = 367) from the United States, Korea and Finland (Table 1)
were used to compare the Adv36-ELISA to the Adv36-serum
neutralization assay (SNA). The SNAs were performed, as
described previously [4,5] (see information S1). In brief, human
sera were serially diluted (two-fold) from 1:2 to 1:128 in 96-well
plates, whereas the rabbit sera were diluted from 1:40 to 1:10240.
Each serum sample and the positive rabbit control serum were run
in duplicate with additional appropriate controls [4,5]. Serum
samples without CPE in dilutions of 1:8 or higher were considered
positive. Disparate readings with one reading above and one
below the cutoff value were considered equivocal.
ELISA for Antibodies Against Adv36
The investigation is presented according to the Standards for
the Reporting of Diagnostic Accuracy (STARD) (http://stard-
statement.org/). The analyses were performed by researcher
blinded to any phenotypic and SNA data. 96-well ELISA
microplates were coated overnight at 4uC with recombinant
Adv36 fiber protein fragment fused with maltose binding protein
(10 mg/ml, Obetech, Richmond, VA). After washing step,
Table 2. Clinical characteristics of the study groups.
Obese children SDPP and SMC females and males Obesity surgery clinic females
BMI,25 kg/m2 28#BMI,35 kg/m2 BMI$35 kg/m2 BMI$35 kg/m2
nfemales, nmales 113, 108 336, 219 301, 207 27, 11 241, 0
Antilipid drug [nyes/nno] 15/459 27/405 1/37 12/229
Total cholesterol [mM]a 4.0 (3.4, 4.5)p 6.3 (5.6, 7.0) 6.4 (5.9, 6.9) 6.4 (5.6, 7.9) 4.6 (4.0, 5.4)p
LDL [mM] 2.6 (2.0, 3.1)p
HDL [mM] 1.0 (0.80, 1.2)p
Triglycerides [mM]a 1.1 (0.70, 1.6)p 1.0 (0.87, 1.6) 1.6 (1.2, 2.3) 2.1 (1.4, 3.3) 1.2 (0.89, 1.5)p
Glucose [mM] 5.2 (4.9, 5.5)p 4.7 (4.4, 5.0) 5.0 (4.7, 5.3) 5.0 (4.7, 5.6) 5.3 (5.0, 5.6)p
Insulin [mU/ml] 14.4 (9.9, 21.5)p 12.0 (10.0, 15.0) 16.0 (13.0, 19.0) 22.0 (16.5, 27.0) 9.5 (6.2, 14.0)
HOMA-IRb 2.5 (2.0, 3.2) 3.7 (2.8, 4.6) 4.8 (3.9, 6.8) 2.2 (1.4, 3.4)
Insulin sensitivity (Si) 2.3 (1.5, 3.9)
Acute insulin response (AIR) 893 (589, 1470)
No individual had diabetes. The lean children group is not included.
Values are median (25th,75th percentile). SMC samples (81 lean females (BMI,25 kg/m2) and 76 overweighed/mildly obese females (28#BMI,35 kg/m2)) had no data
for these characteristics but are included in the total n. For SDPP, blood lipid data was available from 172 lean, 103 overweighed/mildly obese and 9 severely obese
individuals. Other data was available from all SDPP individuals. The lean children group is not included here since these characteristics were unknown for them.
aThose on pharmacological treatment for high blood lipid levels (statins or fibrates) were excluded.
bHOMA-IR was not analyzed in children because limited correlation with Si in children [41].
pFasting plasma levels. Otherwise, data are fasting serum levels.
doi:10.1371/journal.pone.0041652.t002
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blocking with 20 mg/ml of bovine serum albumin for 1 h, and
another washing step, a mixture of horse radish protein (HRP
conjugated coating protein, Obetech, Richmond, VA) and the
competitor protein recombinant maltose binding protein
(62.5 mg/ml, MBP, Obetech, Richmond, VA) as well as serum
was added to each well. Each 96-well plate had one positive serum
control (50 ml positive rabbit control serum (diluted 1:80)
(Obetech, Richmond, VA)), one background control (50 ml of
blocking buffer), and at least one control serum known to be at the
cutoff value for positive ELISA score being human serum (50 ml)
and rabbit serum (50 ml of dilution 1:1280). After 1 h of incubation
and subsequent washing, TMB substrate solution (3,39,5,59 –
tetramethylbenzidine, Thermo Scientific 34028, Rockford, IL) was
added to each well, and reaction stopped after ,25 min with 1M
HCl. The plate was read at a wavelength of 450 nm. All samples
were run in duplicate. The positive serum control must have an
optical density (OD450) reading greater than 1.5, and the
background control must have a reading below 0.06 or the assay
was invalid. The negative human control serum should be within
OD45060.05 from its reference value. ELISA cutoff for positive
score was based on analysis of human serum samples with known
Adv36-SNA status. Thereafter, the OD450 reading from the
1:1280 dilution of the positive rabbit serum was used as cutoff
marker for positive ELISA score since it gave a signal
corresponding to the defined ELISA cutoff. An OD450 equal or
greater than this value in both duplicates was scored as a positive
assay for Adv36 antibodies. A reading of less than this value in
both duplicates was scored negative. Disparate readings with one
reading above and one below the cutoff value were considered
equivocal and the sample was reanalyzed in duplicate. A sample
with repeat analyses was considered to be positive if .50% of the
replicates were positive with an OD450 higher than the cutoff
value. Hence, data from a reanalyzed serum sample were used
only if the reanalysis provided consistency between the duplicates.
Human serum samples (n = 367) from United States, Korea and
Finland were used to compare the Adv36-ELISA scores to the
Ad36-SNA scores. These samples were not reanalyzed. For
protocol details see information S1.
Statistical Analysis
In the children Adv36 positivity in the ELISA was analyzed for
statistically significant association to obesity using the Pearson’s
chi-square test, along with estimation of odds ratio (OR) and 95%
confidence interval (CI), and using logistic regression including
Adv36 status, sex and age as covariates. For the children the
following quantitative clinical outcome variables were analyzed
with regard to Adv36 status: BMI SDS [24], levels of fasting
plasma triglycerides, total cholesterol, LDL, HDL, glucose, insulin,
Si and AIR. To normalize the distribution of the quantitative
variables they were transformed by the natural logarithm (ln). The
association analyses were performed using ANCOVA with Ad36
status, age and sex as independent factors. Also BMI SDS was
included as independent factor for outcome variables other than
BMI SDS. The distribution of the residuals was normal.
For the adults, association between Adv36 positivity and obesity
was tested in each sex separately using the Pearson’s chi-square
test, and logistic regression with Adv36 and age as covariates.
Association between Adv36 status and marker for high levels of
circulating blood lipids, i.e. being on pharmacological treatment
for high blood lipid level and/or having high triglyceride level, was
tested using Pearson’s chi-square test, and logistic regression with
Adv36, cohort ID, BMI group, sex and age as covariates.
Individuals known to not be on treatment but missing data on
blood triglyceride levels were excluded from this analysis. A
circulating triglyceride level above the normal interval (0.45–
2.6 mmol/l), i.e. .2.69 mmol/l was regarded as high. The
quantitative clinical variables for adults analyzed for association
to Adv36 status were BMI, waist circumference, levels of fasting
levels of triglycerides, total cholesterol, glucose, insulin and
HOMA-IR (higher level reflecting higher insulin resistance). The
quantitative variables were transformed by the natural logarithm
(ln) and association between Adv36 positivity and clinical data was
analyzed using unpaired ttest and ANCOVA with age and BMI as
covariates for normally distributed variables, and using Mann-
Whitney U tests for non-normally distributed variables. If samples
from SDPP and clinical patients were combined in the quantita-
tive outcome variable analysis, ANCOVA was applied using age,
cohort-ID and BMI as additional covariates. The distribution of
the residuals was normal. If female and male samples were
included in the same analysis, sex was used as additional covariate
in the ANCOVA. For quantitative analysis of triglyceride and
cholesterol levels, individuals on pharmacological treatment for
high blood lipid levels were excluded. All analyses were performed
using SPSS version 19. Reported p-values are two-tailed. A two-
tailed p-value below 0.05 was regarded as significant.
Results
The study groups used within the different studies (study 1, 2, 3a
and 3b) are listed in Table 1.
An ELISA for the Detection of Antibodies Against Human
Adenovirus-36 (Study 1)
An ELISA detecting antibodies against a recombinant Adv36
coat protein (the fiber protein) in serum was developed. A total of
367 human sera from five sets of samples from different
geographical areas were used to compare this ELISA with the
standard method, the serum neutralization assay (SNA). For some
of the sets, individual serum samples were selected based on prior
SNA results, so the frequency of antibody positive tests did not
reflect population Adv36 infection prevalence. The assays were
run with the researcher blind to the results of the other assay.
Table 3 shows the comparison between the ELISA and the SNA.
Of the samples positive in the SNA, 74.3% were positive also in
the ELISA (Standard error of proportion (SEP) = 7.4; 26 ELISA-
positive of 35 SNA-positive samples), and of the samples negative
in the SNA 63.1% were negative also in the ELISA (SEP =2.8;
185 ELISA-negative of 293 SNA-negative samples). The propor-
tion of samples with equivocal scoring was lower in ELISA (3.3%)
compared to in SNA (7.6%) (OR=0.4, p = 0.015). The between-
duplicate correlation of Adv36-ELISA OD450 values was very
good (r = 0.996, n = 367, Pearson’s correlation coefficient).
Data from rabbit serum samples suggested that the higher rate
of seropositivity in the ELISA in comparison to the SNA might in
part be due to the ELISA detecting lower titers of Adv36-
Table 3. Comparison between the ELISA and the serum
neutralization assay (SNA) for Adv36 antibody detection.
ELISA-negative ELISA-positive ELISA-equivocal Totals
SNA-negative 185 108 9 302
SNA-positive 9 26 2 37
SNA-equivocal 16 11 1 28
Totals 210 145 12 367
doi:10.1371/journal.pone.0041652.t003
Adv36 and Obesity
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antibodies than the SNA did. Serum samples collected from
rabbits inoculation with killed Adv36 were analyzed in parallel
using the ELISA and the SNA. The titration curve (steps of 1:2)
showed that the ELISA was positive down to dilution 1:1280
(OD450$0.12) (Fig. 2) whereas the SNA did not detect Adv36
antibodies in dilutions greater than 1:160 (data not shown).
There is a high degree of homology of proteins among
adenoviruses, for Adv36 especially to other adenoviruses belonging
to group Adv-D [3]. Although the ELISA-based antigen was
selected to be as specific as possible, cross reactivity with other
non-Adv36 adenoviruses may exist. The extent to which the
Adv36-ELISA cross reacted with two other Adv-D adenoviruses,
human adenovirus-37 (Adv37) and human adenovirus-9 (Adv9),
were roughly estimated. Thirty-one samples that were negative for
Adv36 by Adv36 SNA were evaluated for antibodies to Adv37 and
for antibodies to Adv9 by their respective serum neutralization
assays. Of the 31 samples, 11 were positive for any or both of
Adv37 and Adv9 (one for Adv37 alone, five for Adv9 alone, and
five for both Adv37 and Adv9). Of these 11 samples, 5 were
positive for Adv36 by ELISA (Table 4). Four of the 6 Adv37-
positive samples were positive in the ELISA. While this may
indicate cross reactivity of the ELISA with Adv37 and potentially
explain some non-specificity of the ELISA versus Adv36 SNA, the
rate of ELISA-positivity in relation to positivity of Adv37 and
Adv9 SNAs (5 of 11= 45%) was not significantly different to that
of ELISA-positivity among samples negative for Adv36 SNA (108
of 293= 37%) (p = 0.75).
The average exclusion rate, i.e. the average proportion of
samples being ‘‘equivocal’’, in the 9 sample BMI-groups (children
and adults) reported below was 3.9%. The exclusion rate was not
significantly different between the BMI-groups (p.0.3).
Antibodies Against Human Adenovirus-36 are Present in
Serum from Adults and Children in Sweden (Study 2)
The Adv36-ELISA was used to analyze serum samples from the
population-based cohorts SDPP and SMC from the adult
Stockholm and Uppsala population, serum samples from anony-
mous blood donors from Stockholm and serum samples from lean
children (16–17 years old) from Stockholm. Serum samples
collected between 1992 and 1998 from 180 lean (BMI,25 kg/
m2) adults living in Stockholm County and aged 35–55 years,
selected from SDPP, had a prevalence of Adv36-positive serology
of 7.2% (Fig. 3). Serum samples collected in 2002–2006 from lean
Figure 2. ELISA titration curve. ELISA titration curve of serum from rabbit inoculated with Adv36. Cutoff for positivity in the ELISA is at rabbit
serum dilution 1:1280 (OD450 = 0.12), that is in the low linear region. The average optical density at 450 nm of three experiments, each in duplicate,
from one rabbit is shown. Error bars indicate SEM. Similar data were obtained from two additional rabbits.
doi:10.1371/journal.pone.0041652.g002
Table 4. Proportion Adv36-ELISA-positive samples among
those scoring negative or positive for Adv37 and/or Adv9.
Adv9-
negative
Adv9-
positive
Adv9-
equivocal Totals
Adv37-negative 9/17 1/5 2/3 12/25
Adv37-positive 0/0 4/5 0/1 4/6
Adv37-equivocal 0/0 0/0 0/0 0/0
Totals 9/17 5/10 2/4 16/31
All samples scored negative for Adv36 in the serum neutralization assay.
doi:10.1371/journal.pone.0041652.t004
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adults in Stockholm, 219 males and 255 females aged 46–66 years
selected from SDPP, had a prevalence of 15.6% among females
and 19.5% among males, with combined prevalence of 17.6% in
males and females. Serum collected 2004 from 81 lean
(BMI,25 kg/m2) postmenopausal females in Uppsala, selected
from SMC, had an Adv36-positive serology prevalence of 14.1%.
Also serum samples from 203 lean children aged 16–17 years from
high-schools in Stockholm collected 2004–2006 were analyzed for
prevalence of Adv36-positive serology. Similar to the prevalence in
adults 2002–2006, the children had a prevalence of 20.1%. Hence,
the prevalence of Adv36 in Stockholm increased from ,7% in
1992–1998 to 15–20% in 2002–2006. To estimate the prevalence
of Adv36 positivity prevalence in 2009, serum samples were
collected in 2009 from 89 healthy anonymous blood donors in
Stockholm (34 men and 55 females aged 19–69 years) and
analyzed for Adv36 serology. The prevalence of positive Adv36
serology was 18.2%. Hence, marker for ongoing or past Adv36
infection was present in the adults and children population in the
Stockholm-Uppsala area of Sweden. The prevalence of Adv36 in
Stockholm increased from ,7% in 1992–1998 to 15–20% in
2002–2006, and was stable until 2009. The prevalence of positive
Adv36 serology was similar in adults and children.
Adv36 is More Common in Obese than Lean Swedish
Children (Study 3a)
Children referred to pediatric obesity clinic for obesity as well as
lean controls from high schools (Fig. 1), all cases and controls being
from Stockholm County, were analyzed for Adv36 antibodies in
serum using ELISA. The obese/overweight children had a higher
prevalence of positive Adv36 serologic status (28.8%) compared to
the lean controls (20.1%) (Fig. 4A). Hence, Adv36 positivity was
statistically more common in obese/overweight than in lean
children (OR=1.6, 95% CI: 1.0–2.6; x2(1) = 3.9, p = 0.047). This
was found also by a logistic regression analysis where Ad36 status,
sex and age were used as covariates (Adv36 status: OR=1.7, 95%
CI: 1.0–2.9, p = 0.050; age: b =20.78, SEM: 1.8, p,0.001; sex:
p.0.1) (Table 5). Also, the quantitative BMI SDS variable was
borderline linearly dependent on Adv36 status in the obese/
overweight and lean children (ln(BMI SDS): unstandardized
b= 0.21, SEM =0.11, F = 3.4, p = 0.064; age: b=20.20, SEM
=0.021, F= 87.3, p,0.001, ANCOVA). Blood lipid levels (fasting
plasma triglycerides, total cholesterol, HDL, LDL) were not
different between Adv36-positive compared to Adv36-negative
obese/overweight children (p.0.3), and there was no effect of
Adv36 positivity on glucose, insulin, insulin sensitivity (Si) or AIR
among these samples (p.0.3).
Adv36 is More Common in Severely Obese Females than
Lean or Overweight/mildly Obese Adult Swedish Females
and Men (Study 3b)
Positivity in Adv36 serology was more common among female
patients with severe obesity (BMI$35 kg/m2) that were referred to
obesity surgery clinic in Stockholm between 2008 and 2010 than
among lean healthy Stockholm/Uppsala (SDPP, SMC) females
sampled 2002–2006 (Table 5). The increase in Adv36 positivity
Figure 3. Prevalence of Adv36 in lean Swedes. Prevalence of positive Human adenovirus-36 serology in serum samples from adults and
children living in Stockholm and Uppsala, Sweden, between 1992/1998 and 2009. The Adv36 serology was determined using the Adv36-ELISA. Error
bars indicate standard error of proportion.
doi:10.1371/journal.pone.0041652.g003
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was 1.8-fold (relative risk) compared to lean (BMI,25 kg/m2)
females (OR=2.2, 95% CI= 1.4–3.2; x2(1) = 13.5, p = 0.0002),
and 2.3-fold compared to overweight/mildly obese
(28#BMI,35 kg/m2) females (OR=2.7, 95% CI= 1.7–4.2;
x2(1) = 19.9, p,0.00005). Including also severely obese
(BMI$35 kg/m2) females not referred to the obesity clinic but
enrolled in SDPP resulted the same association, 1.7-fold more
prevalent Adv36 positivity compared to in lean females (OR=2.0,
95% CI= 1.3–3.0; x2(1) = 11.4, p = 0.0007) and 2.1-fold more
prevalent Adv36 positivity compared to overweight/mildly obese
females (OR=2.5, 95% CI= 1.6–3.9; x2(1) = 17.6, p,0.00005)
(Table 5, Fig. 4B). No difference in prevalence of Adv36 positivity
was detected between lean and overweight/mildly obese females
(p.0.1). Due to a low number of severely obese males (n = 11),
Adv36 association to severe obesity in males could not be
analyzed. However, no difference in Adv36 positivity was found
between females and males in lean and overweight/mildly obese
groups (p.0.24), and no difference in prevalence of Adv36
positivity was detected among males between lean (BMI,25 kg/
m2) and overweight/mildly obese (28#BMI,35 kg/m2) (p.0.1)
(Table 5, Fig. 4B). The age distribution differed between the
severely obese females compared to the lean and overweight/
mildly obese females and males (severely obese females: Mean 6
SD: 42.0610.6 years; overweight/obese females and males:
57.366.8 years; lean females and males: 57.366.5 years). How-
ever, this difference in age distribution did not influence the Adv36
association to female severe obesity, compared to BMI,35 kg/
m2, since logistic regression with Adv36 status and age as
covariates showed OR=2.1 (95% CI: 1.3–3.5, p= 0.004) for
Adv36 status.
Previous studies on Adv36 and obesity have mainly used BMI
= 30 kg/m2 as cutoff. Using BMI = 30 kg/m2 as cutoff between
‘obese’ and ‘lean’ groups in this study the association between
Adv36-positive serology and obesity was still present for females
(OR=1.5, x2(1) = 5.6, p = 0.018). However, the statistical signif-
icance was lower compared to studying severe obesity
(BMI$35 kg/m2), as expected from the proportions listed in
Table 5. Further, in the obese group (BMI BMI$30 kg/m2) of
females Adv36 positivity was associated with higher BMI
(p = 0.014, Mann-Whitney U). In the obese females and males
(BMI$30 kg/m2) HOMA-IR, that reflects insulin resistance,
tended to be lower for those Adv36-positive than those Adv36-
negative using Adv36 status, cohort ID and sex as fixed factors and
age and BMI as covariates (Adv36: F=3.0, p = 0.084; cohort ID:
Figure 4. Association between Adv36 and obesity. A) Higher proportion of children with positive Adv36 serology among pediatric obesity
patients (BMI SDS: 2.2–10.5) than lean (BMI SDS:21.421.8) children from high schools in Stockholm. B) Higher prevalence of positive Adv36 serology
among severely obese (BMI$35 kg/m2) females compared to lean (BMI,25 kg/m2) and overweight/mildly obese (O.w./mild obese) (28,BMI,35 kg/
m2) females in Stockholm and Uppsala. Error bars indicate standard error of proportion. Due to a low number of severely obese males (n = 11), Adv36
association to severe obesity in males could not be analyzed. However, no difference in Adv36 positivity was found between females and males in
lean and overweight/mildly obese groups, and no difference in prevalence of Adv36 positivity was detected among males between lean and
overweight/mildly obese.
doi:10.1371/journal.pone.0041652.g004
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F=70.9, p,0.005; sex: p.0.1; age: p.0.1; BMI: F=23.7,
p,0.005; ANCOVA).
Having a high triglyceride level (.2.69 mmol/l) and/or being
on pharmacological treatment for high circulating blood lipids
(statins or fibrates) was less common among those Adv36 positive
than among those Adv36 negative males and females (OR=2.4,
95% CI: 1.2–4.9, x2(1) = 9.6, p = 0.013). This was verified using
logistic regression with Adv36 status, cohort ID, BMI-group, sex
and age as covariates (Adv36: OR=2.2, p = 0.039). However,
quantitative levels of circulating triglycerides, cholesterol, glucose
or insulin were not associated with Adv36 positivity in any of the
three groups lean, overweight/mildly obese, or the severely obese
group (p.0.1).
Discussion
We show here that Adv36 positive serology, determined by an
ELISA based on the Adv36 fiber protein, is associated with
pediatric obesity (OR point estimate = 1.6) and severe obesity in
adult females (OR point estimate = 2.0–2.7), with consequently
approximately 1.5 to 2-fold increase in Adv36 positivity in cases
compared to lean and overweight individuals. The individuals
studied, including 424 children (10 to 18 years old), 1522 well-
characterized adult females and males and 89 anonymous blood
donors, were residing in central Sweden, Stockholm and Uppsala
cities. The prevalence of Adv36 positivity in lean individuals
residing in these areas increased from ,7% in 1992–1998 to 15–
20% in 2002–2006, and was stable until 2009. The rise in Adv36
positivity over time paralleled the increase seen in obesity in
Sweden, which approximately doubled in prevalence between
1990 and 2005 [28]. The association with obesity was studied in
samples collected in 2002–2010.
The increased prevalence of Adv36 positivity in obese children is
in agreement with previously reported studies, using the serum
neutralization assay (SNA) for Adv36 scoring, showing 2–3-fold
increased prevalence of Adv36 positivity in children from SanDiego
(nnonobese = 57 and nobese = 67) and South Korea (nnonobese = 59 and
nobese = 259) [17,18]. Adv36 positivity was also associated with
increased BMI among 84 obese children from South Korea [19].
The prevalence of Adv36 positivity of 29% in the Swedish obese
children was similar to the 22–30% Adv36 positivity in the obese
children in the three studies from San Diego and South Korea [17–
19]. The samples from these studies were collected after 2005 with
age range of the children (8 to 15–18 years) similar to that of the
children in this Swedish report.
The increased prevalence of Adv36 positivity in Swedish
severely obese females compared to non-severely obese individuals
is in agreement with the report of a 3-fold increase in SNA-based
Adv36 positivity in obese compared to lean adults from Wisconsin,
Florida and New York (nlean = 142 and nobese = 360) sampled
1995–1999 (p,0.001). Similar to among children, ,30% of the
obese adults were Adv36 positive [13]. In addition, twins
discordant for Adv36 status showed an association between
Adv36 positivity and increased BMI [13]. Likewise, Adv36
positivity was 2-fold higher (prevalence 65%) in obese compared
to non-obese Italian adults (nobese = 68 and nnonobese = 135) [15]
and associated with greater BMI in Italian non-alcoholic fatty liver
disease patients (n = 65) from Italy sampled 2007–2008 (n= 65)
[16]. On the other hand, no association was found between BMI
and Adv36 positivity in Dutch/Belgian adults (n = 509) with
generally low prevalence of Adv36 positivity (5.5%) [29], nor
among US military personnel (nobese = 150 and nlean = 150)
showing an overall 36% Adv36 positivity [30]. Na et al found
slightly higher prevalence of Adv36 antibodies (40% seropositivity)
in overweight adults compared to lean adults (33% seropositivity)
from South Korea [14].
That Adv36-obesity association in previous reports is less
consistent in adults than in children maybe because other risk
factors for overweight/obesity, such as life style, may have had a
longer time to be expressed in adults than in children, and hence
mask an Adv36 effect in adults. Also, children may have had less
possibility to build up a protective immune response against Adv36
infection by exposure to other Adv36-cross reacting adenoviruses.
Further, the antibody response to vaccination against virus has
been shown to decrease with age [31] and BMI [32–34]; although
there is no evidence for higher antibody titer against Adv36 in
Table 5. Association for Adv36 positivity to obesity.
Study group Adv36pos Adv36neg x
2, p-value x2, p-value
% (n) % (n) vs BMI,25 kg/m2 vs 28#BMI,35 kg/m2
Children
Overweight/obese (BMI SDS: 2.2–10.5)a 28.8 (57) 71.2 (141) 3.9, 0.047
Lean (BMI SDS: 21.421.8)b 20.1 (38) 79.9 (151)
Females
Severely obese (BMI$35 kg/m2)c 28.4 (66) 71.6 (166) 13.5, 0.0002 19.9, ,0.00005
Severely obese (BMI$35 kg/m2)c, d 27.0 (70) 73.0 (189) 11.4, 0.0007 17.6, ,0.00005
Overweight/mildly obese (28#BMI,35 kg/m2)d 12.6 (37) 87.2 (252)
Lean (BMI,25 kg/m2)d 15.6 (50) 84.4 (270)
Males
Severely obese (BMI$35 kg/m2)d 10.0 (1) 90.0 (9)
Overweight/mildly obese (28#BMI,35 kg/m2)d 15.2 (31) 84.7 (173)
Lean (BMI,25 kg/m2)d 19.5 (42) 80.3 (173)
aPediatric obesity clinic center patients.
bHigh school children.
cAdult obesity surgery clinic patients.
dSDPP and SMC participants.
doi:10.1371/journal.pone.0041652.t005
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young compared to in old persons. However, it is possible that
over time an Adv36 antibody titer in a person decreases to
undetectable level. For example, a decline in antibody titer and T-
cell response during the first year after antiviral vaccination was
more pronounced in obese adults [35].
Nevertheless, we found Adv36 positivity to be associated with
obesity in children, and to severe obesity in females, but not to
mild obesity. Adv36 association with severe obesity in males was
not investigated due to lack of samples.
Previous findings from in vitro studies of human tissue and in vivo
studies in chicken, rodents and primates show that experimental
infection with Adv36 induces fat accumulation in cells, preadipo-
cyte proliferation, adipocyte differentiation, and body fat increase
[4–12]. This supports the view that the Adv36-obesity association
found in human serum samples reflects obesity as a result of the
infection, rather than the possibility that the Adv36-obesity
association reflects an obese state being more susceptible to
Adv36 infection. A 2-fold increased risk for severe obesity by
Adv36 with a prevalence of ,15% in the control population, may
be comparable to the increased risk of the currently known BMI-
influencing genetic variations which together are reported to
explain 1.5% of the variation of BMI according to genome-wide
association analysis [36,37].
We also found that high levels of circulating lipids, indicated by
current treatment with statins or fibrates and/or a triglyceride
level above the normal interval in untreated individuals, were less
common in Adv36 positive compared to Adv36 negative adults.
Accordingly, Adv36-associated obesity has been reported to have a
good metabolic profile with low levels of blood lipids in animal [5]
and in adult humans [13].
Further, we found a tendency, but not statistically significant
(p = 0.084), for an association between Adv36 positivity and
increased insulin sensitivity, measured as lower HOMA-IR in
obese non-diabetic females and males (BMI$30 kg/m2). Dhur-
andhar et al. [22] recently reported that natural Adv36 infection
predicts better glycemic control in humans and showed additional
data supporting that experimental Adv36 infection of animals
increases adiposity and improves glycemic control. They have
proposed that Adv36-induced increased glucose uptake by adipose
tissue and skeletal muscle, increased adiponectin signaling, and
reduced hepatic glucose output contribute to systemic glycemic
control in Adv36- infected animals. In in vitro studies Adv36
induced peroxisome proliferator-activated receptor-c and adipo-
genesis and concomitantly increased cellular glucose uptake via a
Ras-mediated, phosphatidyl inositol 3-kinase (PI3K)-dependent
up-regulation of glucose transporters [20,21].
This paper is the first report of an ELISA assay to detect past
infection with Adv36. Serial dilution of a known positive serum
obtained from rabbits inoculated with killed Adv36 showed that
the ELISA could detect Adv36 antibodies at concentrations 8 imes
lower than the SNA could. This may explain that the ELISA
scored positive for 36.9% of the the Adv36-SNA-seronegative
samples among 367 human serum samples from United States,
Korea and Finland. The specificity of the ELISA might be a
concern as it picks up all antibodies directed against the Adv36
fiber protein fragment used as the ELISA plate coating antigen,
and not only those neutralizing. However, the rate for positive
Adv36-ELISA score in the 11 samples that were SNA-positive for
Adv37 or Adv9 but SNA-negative for Adv36 was similar to that
among the 293 Adv36-SNA negative samples with unknown
Adv37/Adv9 score, suggesting that cross reactivity may be limited,
although it needs to be investigated further in subjects (such as
experimental animals) known to have been exposed only to Ad-
viruses other than Adv36. Adv37, shown to induce obesity in
chicken [38], and Adv9 belong to the same adenovirus-D
subgroup as Adv36 and these three viruses are genomically
substantially homologous. However, the CR1b, CR1c, and fiber
protein genes of Adv36 are quite divergent compared to those of
other Adv-D viruses, such as Adv37 and Adv9; the Adv36 fiber
protein shows only 60–70% homology to the other Adv-D viruses
sequenced [3]. The ELISA scored positive for 74.3% of the
samples positive in the Adv36-SNA. Since the SNA scores signal
from all neutralizing Adv36 antibodies in the serum, whereas the
ELISA measures only antibodies to a fragment of the fiber protein,
the ELISA may fail to detect some samples from true prior Adv36
infection. Hence, the rabbit serum experiments showed that the
ELISA detects lower titers of antibodies to Adv36, but the
concordance test in human samples showed that not all persons
with neutralizing antibodies to Adv36 have those antibodies
detectable by the ELISA. However, the fact that we detect
association between the Adv36-ELISA-signal and the clinical
phenotypes of obesity and insulin sensitivity similar to the
associations with these variables found in previous studies
[19,22] strongly suggests that the Adv36-ELISA indeed measures
prior Adv36 infection. In addition, our data show that the Adv36-
SNA has a higher uncertainty rate, with about twice the rate of
equivocal results compared to the ELISA.
There are some limitations in this study. The sample size was
small (i) for testing cross reactivity between Adv36, Adv37 and
Adv9, (ii) for estimating Adv36 prevalence in samples collected in
Stockholm 1992–1998, (iii) of severely obese adult males. The age
distribution was different between obese/overweight children and
lean children, however, age, sex and BMI SDS was controlled for
in the analysis. For 29% of the obese/overweight children and the
adults studied there was no information available regarding weight
reduction efforts prior to sampling. There was no blood chemistry
data for the lean children and the SMC adult females. Data on
blood lipid levels were missing for a considerable number of SDPP
adult individuals.
To conclude, we developed a rapid ELISA and show that
Adv36 infection is associated with pediatric obesity, severe obesity
in adult females and lower levels of blood lipids, and that those
infected have a tendency for increased insulin sensitivity in non-
diabetic Swedish individuals. These findings agree with previous
studies in vitro, in experimental animal and most human popula-
tion studies. We also show a rising prevalence of Adv36 infection
in Sweden from the period of 1992 to 2009, the first longitudinal
data suggesting an increasing prevalence of Adv36 infection in
parallel to an increase in the prevalence of obesity. These findings
address comments in a recent review arguing for the need of
further epidemiological studies to establish the link between viral
infection and obesity in man [39]. The importance of a rapid
Adv36 detection assay that may be used clinically is demonstrated
by the study of Trovato et al [40] which demonstrated that a
positive clinical response of non-alcoholic fatty liver disease to
nutritional treatment was enhanced in Adv36-positive compared
to Adv36-negative patients. This study suggests that detection of
Adv36 in patients may guide the selection of treatment. Further
studies on Adv36 association with metabolic states in large
population cohorts are justified.
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